Janssen Search
Search results
Johnson & Johnson spotlights nipocalimab at FMF Congress 2024 – the first and only FcRn blocker to be studied in maternal fetal diseases
Jun 27, 2024 The Phase 3 AZALEA and Phase 3 FREESIA clinical studies are enrolling pregnant individuals who are at risk for severe HDFN and FNAIT These rare and potentially life-threatening alloantibody diseases affecting pregnant individuals and their ...
Johnson & Johnson’s nipocalimab granted U.S. FDA Breakthrough Therapy Designation for the treatment of individuals at high risk for severe hemolytic disease of the fetus and newborn (HDFN)
Feb 09, 2024 United States Breakthrough Therapy Designation for nipocalimab based on results from the Phase 2 UNITY clinical trial for HDFN Phase 3 clinical trial enrollment underway, representing the only therapy reported to be under clinical development ...
Late-breaking results show nipocalimab significantly improves Sjögren’s disease activity in a Phase 2 study
Jun 15, 2024 Patients who received nipocalimab 15 mg/kg demonstrated a greater than 70 percent relative average improvement on the primary endpoint compared to patients who received placebo Sjögren’s disease is a chronic, debilitating, and prevalent ...
Focus on Chronic Pain
Pain (Chronic Neuropathic and Non-Neuropathic) Our Areas of Interest for Collaboration Novel Therapeutic Agents in Phase 2b or Later for Moderate-to-Severe Chronic and Neuropathic Pain Biomarkers and Diagnostics Preventive or disease modifying agents for ...
RYBREVANT®▼ (amivantamab) in combination with chemotherapy is the first therapy approved by the European Commission for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations
Jun 28, 2024 Approval is supported by the Phase 3 PAPILLON study, which showed amivantamab plus chemotherapy significantly reduced the risk of disease progression or death by 60 percent compared to chemotherapy alone 1 BEERSE, BELGIUM (28 June 2024) – ...
World Kidney Day
This year’s theme is "Living Well With Kidney Disease" Event Date: Thursday, March 11, 2021- 11:30 Event End Date: Thursday, March 11, 2021- 11:30 ...
TECVAYLI® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma
Feb 20, 2024 United States Biweekly dosing with TECVAYLI ®, the first approved BCMA-targeting bispecific antibody, provides patients with dosing flexibility HORSHAM, Pa., February 20, 2024 – Johnson & Johnson announced today that the U.S. Food and ...
U.S. FDA Oncologic Drugs Advisory Committee recommends CARVYKTI® (ciltacabtagene autoleucel) for the earlier treatment of patients with relapsed or refractory multiple myeloma
Mar 15, 2024 United States FDA ODAC unanimously votes 11 to 0 supporting favorable risk-benefit assessment of CARVYKTI® based on results from the Phase 3 CARTITUDE-4 study RARITAN, N.J., March 15, 2024 – Johnson & Johnson announced today that the U.S. ...
TALVEY® (talquetamab-tgvs) demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma
Jun 14, 2024 24-month overall survival rate of 67 percent achieved with TALVEY® 0.8 mg/kg biweekly dosing in the Phase 1/2 MonumenTAL-1 study MADRID (PRNewswire (June 14, 2024) – Johnson & Johnson (NYSE: JNJ) announced today that long-term data from ...
Jeffrey Infante, M.D.
JEFFREY INFANTE, M.D. GLOBAL HEAD, ONCOLOGY EARLY CLINICAL AND TRANSLATIONAL RESEARCH Jeffrey Infante, M.D., is Global Head, Oncology, Early Clinical and Translational Research. He joined Janssen Research & Development in 2017 as Vice President, ...